3 ·Filed Sep 3, 2026

SEPN

Septerna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed28d 16h ago SEC0001193125-26-382268
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

No immediate trading signal. Monitor future Form 4 filings from Patni for any open-market purchases or sales, which would provide insider conviction signals. The appointment itself is neutral for the stock.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d
SEPN ▲ +7.62% at T+5d
NEUTRAL call ✓ call won +7.62% · α vs SPY +8.83% · entry $36.75 → $39.55
Next anchor: T+20d due 4h ago
Latest observation: T+18 +11.14% FF3 residual α
Entry anchored
Sep 3, 2026
via day open
T+1d
+1.69%
call +1.69% · α +2.24%
$37.37
settled 28d ago
T+5d
+7.62%
call +7.62% · α +8.83%
$39.55
settled 21d ago
T+20d
—
call — · α —
—
due 4h ago
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Rajiv Patni, M.D., has been appointed Chief Medical Officer of Septerna, Inc. and filed a Form 3 initial statement of beneficial ownership, along with a limited power of attorney authorizing certain company officers to execute future Section 16 filings on his behalf. This is a routine administrative filing for a new officer and contains no financial data, trading activity, or material corporate event.

Key Facts

  • Rajiv Patni, M.D. appointed as Chief Medical Officer of Septerna, Inc.
  • Form 3 filed on 2026-09-03 with a period of report of 2026-08-24
  • Limited power of attorney executed on 2026-08-18 authorizing Jeffrey Finer, Elizabeth Bhatt, Gil M. Labrucherie, Mark A. Wilson, and Ran Xiao to file Section 16 forms
  • No beneficial ownership or trading data disclosed in the filing

Financial Impact

No financial impact — routine officer onboarding filing with no disclosed ownership or transactions.

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-382268
Document: 0001193125-26-382268-index-headers.html0001193125-26-382268
Document: 0001193125-26-382268-index.html0001193125-26-382268
Document: 0001193125-26-382268.txt0001193125-26-382268
17 reports for SEPN
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+60▲ +55.96%Apr 13, 2026
Filters
Rows
Reports for SEPN — sortable, filterable
TypeNow
Sep 10, 2026
21d ago
Press Release
NEUTRAL ★ 2/10
$38.51 $38.69▲ +0.47%▲ +0.69%$38.27 (−0.62%)
Sep 3, 2026
28d ago
3
NEUTRAL ★ 2/10
$36.75 $39.55▲ +7.62%▲ +8.83%$38.27 (+4.14%)
Aug 25, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$41.30 $37.68▼ −8.77%▼ −8.23%$38.27 (−7.34%)
Aug 14, 2026
6w ago
Insider Cluster
BEARISH ★ 7/10
$44.20 $40.52▲ +8.33%▲ +7.14%$38.27 (+13.42%)
Aug 14, 2026
6w ago
Insider Cluster
BEARISH ★ 6/10
$44.20 $40.52▲ +8.33%▲ +7.14%$38.27 (+13.42%)
Aug 12, 2026
7w ago
144
BEARISH ★ 5/10
$45.14 $40.79▲ +9.64%▲ +7.67%$38.27 (+15.22%)
Aug 12, 2026
7w ago
144
BEARISH ★ 5/10
$45.14 $40.79▲ +9.64%▲ +7.67%$38.27 (+15.22%)
Aug 10, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$47.76 $43.80▼ −8.29%▼ −7.89%$38.27 (−19.87%)
Aug 10, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$47.76 $43.80▼ −8.29%▼ −7.89%$38.27 (−19.87%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$34.00 $37.84▲ +11.29%▲ +10.36%$38.27 (+12.56%)
Showing 10 of 17

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access